- Home
- TRVI vs PENN Comparison
TRVI vs PENN Comparison
Compare TRVI & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | PENN |
|---|---|---|
| Founded | 2011 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TRVI | PENN |
|---|---|---|
| Price | $16.07 | $17.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $21.55 | $20.83 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $6,362,900,000.00 |
| Revenue This Year | N/A | $6.85 |
| Revenue Next Year | N/A | $3.83 |
| P/E Ratio | ★ N/A | $74.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.65 | $11.65 |
| 52 Week High | $20.22 | $22.36 |
Technical Indicators
Market Signals| Indicator | TRVI | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 36.50 |
| Support Level | $13.08 | $16.24 |
| Resistance Level | $15.96 | $18.25 |
| Average True Range (ATR) | 0.72 | 0.59 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 3.82 | 31.00 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 42 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 81% of total sales in 2025; 19% was from the interactive segment, which includes sports, i-gaming, and media revenue. The retail portfolio generates low-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/i-gaming technology and clientele, helping it form a leading digital position.